A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
Sign Up to like & getrecommendations! Published in 2018 at "Cephalalgia"
DOI: 10.1177/0333102418771376
Abstract: Objectives The primary and secondary objectives of this phase 1 study were to evaluate the pharmacokinetic profile, safety, and immunogenicity of fremanezumab subcutaneous (sc) doses tested in phase 2 and 3 trials (225 mg, 675 mg and… read more here.
Keywords: caucasian healthy; safety; study; japanese caucasian ... See more keywords